ADVFN Logo
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

ADMA Adma Biologics Inc

6.27
0.07 (1.13%)
After Hours
Last Updated: 18:34:34
Delayed by 15 minutes

Period:

Draw Mode:

Volume 3,411,865
Bid Price 6.27
Ask Price 6.28
News -
Day High 6.29

Low
3.06

52 Week Range

High
6.76

Day Low 6.10
Company Name Stock Ticker Symbol Market Type
Adma Biologics Inc ADMA NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.07 1.13% 6.27 18:34:34
Open Price Low Price High Price Close Price Prev Close
6.1999 6.10 6.29 6.27 6.20
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
17,280 3,411,865 $ 6.19 $ 21,129,331 - 3.06 - 6.76
Last Trade Time Type Quantity Stock Price Currency
19:14:42 5 $ 6.28 USD

Adma Biologics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
1.43B 228.22M - 258.22M -28.24M -0.12 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Adma Biologics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No ADMA Message Board. Create One! See More Posts on ADMA Message Board See More Message Board Posts

Historical ADMA Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week6.2256.295.916.101,949,9260.0450.72%
1 Month6.266.765.8956.332,300,6090.010.16%
3 Months5.136.765.025.882,532,8431.1422.22%
6 Months3.346.763.065.062,334,7412.9387.72%
1 Year3.326.763.064.472,234,9672.9588.86%
3 Years1.626.761.012.752,915,7744.65287.04%
5 Years4.576.761.012.792,759,5901.7037.20%

Adma Biologics Description

ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. Its targeted patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disorder or who may be immune-suppressed for medical reasons. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services.

Your Recent History

Delayed Upgrade Clock